02084nam a2200433 i 4500001001300000003000600013005001700019007001400036008004100050040003000091042000800121043001200129074001900141086002200160088008900182110009800271245021400369264006000583300004400643336000800687337001600695338001900711500003600730500002500766500002500791504004100816533010700857776016300964776018001127050002201307650003901329650004101368650003901409650004701448650003201495650004001527650005001567655003301617on1078151833OCoLC20190115102942.0he bmb024bbca181206s2018    dcua    bb   f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  a1019-B-01 (MF)0 aY 4.C 73/8:115-88  aSerial no. 115-88 (United States. Congress. House. Committee on Energy and Commerce)1 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Health,10aExamining the drug supply chain :bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, December 13, 2017. 1aWashington :bU.S. Government Publishing Office,c2018.  avi, 320 pages :billustrations ;c24 cm  btxt  bh2rdamedia  bhe2rdacarrier  aShipping list no.: 2018-0213-M.  a"Serial No. 115-88."  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]e4 microfiches : negative.08iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining the drug supply chainw(OCoLC)104394890908iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining the drug supply chainw(DLC) 2018379840w(OCoLC)1043948698 4aKF27b.E553 2017c 0aDrugsxPrescribingzUnited States. 0aPrescription pricingzUnited States. 0aMedicinexResearchzUnited States. 0aGeneric drugsxDevelopmentzUnited States. 0aCompetitionzUnited States. 0aConsumer protectionzUnited States. 0aHealth services accessibilityzUnited States. 7aLegislative hearings.2lcgft